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ABSTRACT
We report two patients with velo-cardio-facial syndrome (VCFS) who were admitted to our
pediatric endocrinology clinic because of short stature and followed longitudinally until attain-
ment of final height. Both patients followed a growth pattern consistent with constitutional
delay of puberty with normal and near normal final height. Case 2 also had partial growth
hormone (GH) deficiency and severe short stature (height SDS -3.4 SDS), but showed sponta-
neous catch-up and ended up with a final height of -2 SDS. These cases suggest that short
stature in children with VCFS is due to a pattern of growth similar to that observed in consti-
tutional delay of growth and puberty.
Conflict of interest: None declared
INTRODUCTION
Velo-cardio-facial syndrome (VCFS) is
characterized by a typical facial appear-
ance, learning disabilities, congenital heart
defects, hypernasal speech, cleft palate,
short stature and transient neonatal
hypocalcemia. It was first described by
Shprintzen et al(1) in 1978 as a distinct
multiple anomaly syndrome. The specific
genetic cause of VCFS is a deletion in the
long arm of chromosome 22 at the q11.2
band.(2, 3) Distal deletion of 4q and partial
monosomy 10p has also been reported to
cause a syndrome similar to VCFS.(4, 5)
However, genetic defects could not be
detected by fluorescence in situ hybridiza-
tion (FISH) analysis in 10% of VCFS
cases.(6, 7, 8, 9, 10, 11, 12) A spectrum of
phenotypes, often collectively called
CATCH22 (cardiac defect, anomaly of face,
cleft palate, hypoparathyroidism), is associ-
ated with heterozygous deletions of chro-
mosome 22q11.2. This spectrum includes
the overlapping entities, DiGeorge malfor-
mation complex, VCFS, conotruncal anom-
aly face syndrome, and isolated outflow
tract defect of the heart (conotruncal heart
defect: tetralogy of Fallot, truncus arterio-
sus, and interrupted aortic arch).
Postnatal growth deficiency and short
stature are common features of VCFS report-
ed in 36% to 67% of the patients.(13, 14, 15,
16, 17, 18, 19, 20) All patients with 22q11.2
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usedeletion having short stature reported in a
recent study were younger than 10 years of
age.(21) On the other hand, only 10% of adult
patients are reported to be below normal
height.(13) These observations suggest that
short stature in VCFS could be attributable to a
growth pattern similar to constitutional delay.
To our knowledge, there are no longitudinal
studies describing the pattern of growth in
patients with VCFS. Furthermore, partial
growth hormone deficiency has been detected
in 4 patients with 22q11.2 deletion.(22)
Here we report longitudinal growth data
of two patients with VCFS and short stature
who were followed until attainment of final
height. 
CASE REPORTS
Case 1
This female patient was the first child of
healthy, non-consanguineous parents. She
was born at term after an uneventful preg-
nancy with a birth weight of 2800 g. At age
3 years she had an operation for club foot.
At age 11 years and 4 months she was
admitted to our hospital with epileptic
seizure. Her weight was 28 kg and her
height was 138 cm (-2 SDS and -1.9 SDS
respectively by national standards). Her
bone age was 9 years and 3 months
(Greulich Pyle method). Midparental (target)
height was 161 cm (+0.2 SDS). On physical
examination she had a prominent nasal root,
malar hypoplasia, long face, narrow palpe-
bral fissures, high arched palate, long and
slender fingers, scoliosis and umbilical her-
nia (Figure 1a). Hypernasal speech was
noted. The diagnosis of hypoparathyroidism
was made on follow-up, based on the low
calcium (7.1 mg/dL), high phosphorus (6.2
mg/dl) and inappropriately low parathyroid
hormone (32.5 pg/mL) levels. The typical
facial appearance of the patient and her
hypoparathyroid state led us to consider
VCFS. Chromosome 22q11.2 deletion was
demonstrated by FISH analysis using the
specific DNA probe (Figure 2). However, it
has not been possible to perform a parental
FISH analysis in this particular case.
Echocardiography demonstrated atrial septal
defect. Conductive type hearing loss was
detected on the audiogram. WISC-R score
was 66 IQ. The lymphocyte subset analysis
and serum immunoglobulin levels were nor-
mal. Renal ultrasound and thyroid functions
were also normal. Basal ganglia calcification
was not detected on cranial tomography. At
follow-up, catch-up growth was noted dur-
ing puberty (Figure 3). She had menarche at
age of 15.5 years. The patient’s final height
and weight measurements were 159.3 cm
(-0.1 SDS) and 50.8 kg (-0.8 SDS) respective-
ly at age 18 years and consistent with her
target height which was 161 cm (+0.2 SDS). 
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Figure 1: Facial appearance showing prominent nasal root,
malar hypoplasia, long face, narrow palpebral fissures of case
1 (1a) and, depressed nasal bridge, hypoplastic ala nasi, long
filtrum, long face, narrow palpebral fissures, hypertelorism
and slender fingers of case 2 (1b).
1a 1b
Figure 2: 22q11.2 deletion on FISH analysis of case 2.Case 2
A 13 year-old girl was referred to our
pediatric endocrinology clinic for evalua-
tion of short stature. Parents were first
cousins. She was born at term by vaginal
delivery with a birth weight of 2100 g. At
age 11.5 years she had a tonsillectomy/
adenoidectomy operation because of
recurrent otitis media. She had learning
disabilities especially in mathematics at
school and was reported to have attention
deficit hyperactivity disorder. She also had
decreased visual sharpness. On physical
examination her height was 135.8 cm (-3.4
SDS), her weight was 27.7 kg (-2.3 SDS)
while her midparental (target) height was
153.2 cm (-1.2 SDS). Her bone age corre-
sponded to 10 years (Greulich Pyle
method) at the chronological age of 13
years. She had a depressed nasal bridge,
hypoplastic ala nasi, long filtrum, long
face, narrow palpebral fissures, hypertele-
orism, high arched palate and slender fin-
gers (Figure 1b). A high grade systolic ejec-
tion murmur was heard on the left sternal
border and echocardiography revealed
coarctation of aorta and double aortic arch.
Small optic discs and tortuous retinal ves-
sels were demonstrated on ophthalmologic
examination. WISC-R score was 42 IQ.
Diagnosis of VCFS was considered.
However, no deletion in the 22q11.2
region was found by FISH and high resolu-
tion karyotype analysis was normal. The
patient did not have a history of recurrent
infections other than otitis media. She had
normal serum calcium levels and thyroid
hormone levels. A growth hormone (GH)
provocative test by clonidine revealed par-
tial GH deficiency (peak GH 6.5 ng/ml).
The patient was lost to follow up for 3
years. She had undergone a cardiac opera-
tion in this time period. Her menarche had
occurred at age of 14. Her serum insulin
like growth factor I (IGF-I) and IGF bind-
ing protein 3 (IGFBP-3) levels were 188
and 3770 ng/mL respectively and below -2
SDS for her age. The patient’s final height
at 16.5 years was 148.3 cm (-2.0 SDS), 0.8
SDS lower than her target height. However,
a second growth hormone stimulation test
with L-Dopa performed at this time
revealed showed a normal peak serum GH
level (11.7 ng/ml).
DISCUSSION
VCFS is a genetic syndrome with a wide
range of clinical features. We report two
female patients aged 11 and 13 years pre-
senting to our pediatric endocrinology clin-
ic, one with hypocalcaemia and short stature
and, one with short stature and a severe
heart defect. The facial appearance (Fig. 1a
and 1b) and clinical features of these
patients led us to a consider a tentative diag-
nosis of VCFS. 
The growth pattern, age of menarche
and final height of these two cases with
VCFS were consistent with the pattern of
growth of children with constitutional
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Figure 3: Growth chart of case 1 and 2 demonstrating growth
pattern typical for constitutional delay of growth (Circles;
case 1, squares; case 2).delay of growth and puberty as shown in
Figure 3. Patient 1 had a satisfactory catch-
up growth after puberty with a final height
consistent with her midparental target
height. The second patient demonstrated
severe short stature at presentation and
also had partial GH deficiency in the first
GH stimulation test.However, she demon-
strated spontaneous improvement in height
after puberty, suggesting that she also had
a similar pattern of growth. Despite spon-
taneous improvement in her height SDS,
this patient ended up with a short final
height due possibly to intrauterine growth
retardation, transient partial GH deficiency
or cardiac defect.
Short stature is a frequent finding in VCFS
and has been reported to occur in 36% to
67% of these patients.(13, 14, 15, 16, 17, 18,
19, 20) It was postulated to be due to
intrauterine growth retardation, feeding diffi-
culties and congenital heart defects.
However, no difference in the frequency of
short stature was observed in children
with/or without cleft palate or congenital
heart defect in VCFS (21). Patient series
demonstrated that all patients with 22q.11.2
deletion and short stature were younger than
10 years of age (21), but only 10% of the
adult patients were short (13). This pattern of
growth is suggestive of constitutional delay
growth pattern. However, in the literature
available to us, we did not encounter any
longitudinal growth data regarding the
growth pattern of patients with VCFS. It is
noteworthy that both of our patients showed
growth and pubertal patterns typical for con-
stitutional delay of growth and puberty.
Four patients with 22q11.2 deletion and
short stature were described to have partial
GH deficiency and abnormalities in IGF-
I.(22) All these cases had heights lower than
-2 SDS and they all benefited from GH treat-
ment. Our second case had severe short
stature (-3.4 SDS in height) and failed in the
first GH testing. However, she also showed
an improvement in her height SDS after
puberty and a repeat GH testing showed
normal GH response to stimulation, suggest-
ing that GH deficiency was secondary to a
constitutional delay of growth and puberty.
It is well known that children with constitu-
tional delay of growth and puberty may
exhibit transient GH insufficiency due to
lack of priming effect of sex steroids on pitu-
itary GH secretion.(23, 24, 25)
In our second case, short stature led to
the diagnosis of VCFS with the help of
additional findings which consisted of
conotruncal cardiac defect, high arched
palate, learning disabilities, attention deficit
hyperactivity disorder, and ocular findings.
Although the clinical findings are consistent
with VCFS, we have not detected 22q11.2
deletion or any chromosomal anomaly in
this patient. This may be due to the fact
that deletion of 22q11.2 region is not
detectable by extensive FISH analysis in
approximately 10% of patients who are
clinically diagnosed as 22q11.2 deletion
and our patient may have been in this 10%
group.(6, 7, 8, 9, 10, 11, 12) Another possi-
bility in this patient could be an autosomal
recessive mutation causing VCFS pheno-
type due to parental consanguinity. 
In conclusion, the longitudinal evalua-
tion of these two patients provide a first
demonstration of a growth pattern in VCFS
which is consistent with a pattern of growth
typical for constitutional delay in growth and
puberty. We suggest that GH stimulation
tests in VCFS children should be reserved to
those with height deficits exceeding –2SD of
their target height.
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